DSD-C087

46,XY DSD · 46,XY · DSD-C087

DSD-C087 · 46,XY DSD · 2026

Genes CYP17A1 · Karyotype 46,XY · Phenotypes HPO:0000062, HPO:0000786, Ambiguous genitalia (HP:0000062), Primary amenorrhea (HP:0000786)

18 years 3 months · 46,XY DSD due to CYP17A1 defect causing 17α-hydroxylase/17,20-lyase deficiency.

Images · 1

Case fields and evidence

Category

46,XY DSD

Age

18 years 3 months

Sex

46,XY; the birth appearance was not recognized as abnormal by the family, raised female; chose female gender after psychological evaluation

Karyotype

46,XY

Genetics

CYP17A1

Phenotypes

Ambiguous genitalia (HP:0000062); Primary amenorrhea (HP:0000786)

Diagnosis

18 years 3 months · 46,XY DSD due to CYP17A1 defect causing 17α-hydroxylase/17,20-lyase deficiency.

Follow-up

After treatment blood pressure dropped markedly and other antihypertensives were gradually stopped; the original gave no long-term reproductive/bone-health follow-up.

General phenotype

Tall stature, overweight/obese, acne; breast Tanner 2, sparse pubic hair, absent axillary hair.

Imaging

Ultrasound and MRI showed no Mullerian structures; bilateral small testes below the superficial inguinal ring; no prostate, seminal vesicles, or epididymides.

Laboratory findings

FSH: 23 IU/L (ref 1-11; time point: visit); LH: 19 IU/L (ref 3-10; time point: visit); 8 AM cortisol: 4.18 µg/dL (ref 5.50-18.60; time point: visit); ACTH: 48 pg/mL (ref 15-40; time point: visit); testosterone: 25 ng/dL (ref 280-960; time point: visit); DHEAS: 45 µg/dL (ref 102-480; time point: visit); estradiol: 20 pg/mL (ref 50-122; time point: visit); renin activity: 1.65 ng/mL/h (ref 0.60-4.20; time point: visit); aldosterone: 0.97 ng/dL (ref 1.60-16.00; time point: visit); serum potassium: 3.3-3.7 mEq/L (ref 3.7-5.6; time point: pre-treatment); progesterone: 5.79 ng/mL (ref <0.50; time point: visit); 17-OHP: 2.65 ng/mL (ref <2.00; time point: visit)

Management

Glucocorticoid replacement with added spironolactone improved blood pressure and hypokalemia, and the original antihypertensives were gradually discontinued; later underwent bilateral gonadectomy, vaginoplasty, and estrogen replacement.

Pathology

The original abstract did not provide detailed gonadal pathology.

Genetic variants

c.157_159delTTC, p.Phe54del

Evidence level

See source

Clinical history

See source

Perinatal history

See source

Family history

See source

Growth and development

See source

External genital examination

See source

Puberty / Tanner

See source

Limitations

See source

Cite this resource

DSD Research Library | 46,XY DSD · 46,XY · DSD-C087 | v1.4.0 | 2026-11-17 | https://dsdatlas.com/en/cases/DSD-C087?version=v1.4.0